A recent study explores the clinical characteristics and treatment strategies for brainstem lesions in children with neurofibromatosis type 1. This research contributes to understanding the complexities of managing this rare condition.

A recent publication discusses rare genetic endocrine tumor syndromes, including von Hippel-Lindau (VHL), neurofibromatosis type 1 (NF1), tuberous sclerosis complex (TSC), and Carney complex. The review highlights the genetic underpinnings and clinical implications of these conditions.

A recent study explores the expectations of physicians among adults with neurofibromatosis type 1 (NF1), highlighting the social constructs that define the 'good doctor.' This research provides insights into patient perspectives that could inform physician training and patient care.

At FDA Rare Disease Day 2026, leaders emphasized the importance of patient-centered innovations and new regulatory pathways to accelerate treatments for rare diseases like neurofibromatosis type 1 (NF1) and pediatric cancers. The event highlighted the role of real-world evidence and flexible trial designs in improving access to therapies for patients historically lacking options.

At FDA Rare Disease Day 2026, leaders emphasized the importance of patient-centered innovations and new regulatory pathways to accelerate treatments for rare diseases like neurofibromatosis type 1 (NF1) and pediatric cancers. The event highlighted the role of urgency and flexibility in drug development, aiming to improve options for families affected by these conditions.